MALARVX, INC.

SEATTLE, WA · Founded 2012 · CIK 0001559688 · Biotech · Private

In vitro culture system for producing Plasmodium falciparum sporozoites for malaria vaccine development

malarvx.com →
Grants
$447K
2 awards
Sector median: 1
Raised
$235K
4 Form D · Aug 2026
2 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$250,000
Private capital raisedForm D · SEC$110,000
Private capital raisedForm D · SEC$1,000,000
Federal grantDepartment of Health and Human Services · Phase I · Biological Equivalence of In Vitro Plasmodium falciparum Culture for Practical Malaria Vaccine Development$230,288
Federal grantDepartment of Health and Human Services · Phase I · Biological Equivalence of In Vitro Plasmodium falciparum Culture for Practical Malaria Vaccine Development$217,162
Private capital raisedForm D · SEC$125,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2944Rayaldee——
2945EPITUNE LLC——
2946Atropos Therapeutics, Inc.——
2947MALARVX, INC.—$235K
2948ENEPRET, INC.——
2949Vitanova Biomedical, Inc.—$8.0M
2950OnCusp Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 1 related persons
  • James DavieDirector · Executive Officer

Patents

USPTO · 0 granted of 2
  • Compositions, Devices, Systems And Methods Relating To Vaccination And Sterile Protection Against Malariaapplication
  • Compositions, Devices, Systems And Methods Relating To Vaccination And Sterile Protection Against Malariaapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.